BCTX (STOCKS)

    Briacell Therapeutics Corp. Common Shares

    $2.740000
    -0.030000 (-1.08%)
    Prev close: $2.770000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Biotechnology
    CEO
    William V. Williams
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $24.19M
    Employees
    4
    P/E (TTM)
    -0.22
    P/B (TTM)
    0.83
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Apr 2026)
    Revenues $0.00
    Nonoperating Income/Loss $475.41K
    Operating Expenses $32.03M
    Research and Development $25.81M
    Other Operating Expenses $6.21M
    Operating Income/Loss -$32.03M
    Income/Loss Before Equity Method Investments $22.35M
    Income/Loss From Continuing Operations After Tax $22.14M
    Income/Loss From Continuing Operations Before Tax $22.14M
    Income/Loss From Equity Method Investments -$218.50K
    Net Income/Loss -$30.98M
    Net Income/Loss Attributable To Noncontrolling Interest -$301.12K
    Net Income/Loss Attributable To Parent -$30.68M
    Net Income/Loss Available To Common Stockholders, Basic -$30.68M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$3.03
    Diluted Earnings Per Share -$3.03
    Basic Average Shares 12,088,205
    Diluted Average Shares 12,088,205
    Assets $27.07M
    Current Assets $25.39M
    Noncurrent Assets $1.68M
    Fixed Assets $349.00K
    Non-current Prepaid Expenses $405.09K
    Other Non-current Assets $924.05K
    Liabilities $3.66M
    Current Liabilities $3.59M
    Noncurrent Liabilities $71.85K
    Equity $23.41M
    Equity Attributable To Noncontrolling Interest -$649.10K
    Equity Attributable To Parent $24.06M
    Liabilities And Equity $27.07M
    Net Cash Flow From Operating Activities -$30.82M
    Net Cash Flow From Operating Activities, Continuing -$30.82M
    Net Cash Flow From Investing Activities -$16.19M
    Net Cash Flow From Investing Activities, Continuing -$16.19M
    Net Cash Flow From Financing Activities $41.43M
    Net Cash Flow From Financing Activities, Continuing $41.43M
    Net Cash Flow -$5.58M
    Net Cash Flow, Continuing -$5.58M
    Comprehensive Income/Loss -$30.98M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$30.98M
    Other Comprehensive Income/Loss $0.00